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OPEN Identification of a Phenylthiazole 
Small Molecule with Dual 
Antifungal and Antibiofilm Activity 
Against Candida albicans and 
Candida auris 
Haroon Mohammad1,7, Hassan E. Eldesouky 1,7, Tony Hazbun2,3, 
1,6*Abdelrahman S. Mayhoub4,5 & Mohamed N. Seleem
Candida species are a leading source of healthcare infections globally. The limited number of antifungal 
drugs combined with the isolation of Candida species, namely C. albicans and C. auris, exhibiting 
resistance to current antifungals necessitates the development of new therapeutics. The present study 
tested 85 synthetic phenylthiazole small molecules for antifungal activity against drug-resistant C. 
albicans. Compound 1 emerged as the most potent molecule, inhibiting growth of C. albicans and 
C. auris strains at concentrations ranging from 0.25–2 µg/mL. Additionally, compound 1 inhibited 
growth of other clinically-relevant yeast (Cryptococcus) and molds (Aspergillus) at a concentration as 
low as 0.50 µg/mL. Compound 1 exhibited rapid fungicidal activity, reducing the burden of C. albicans
and C. auris below the limit of detection within 30 minutes. Compound 1 exhibited potent antibiofilm 
activity, similar to amphotericin B, reducing the metabolic activity of adherent C. albicans and C. auris
biofilms by more than 66% and 50%, respectively. Furthermore, compound 1 prolonged survival of 
Caenorhabditis elegans infected with strains of C. albicans and C. auris, relative to the untreated control. 
The present study highlights phenylthiazole small molecules, such as compound 1, warrant further 
investigation as novel antifungal agents for drug-resistant Candida infections. 
Fungi are ubiquitous in nature with most species being innocuous to humans. However, species of Candida are
responsible for the majority of fungal infections reported in the healthcare setting globally. Candida infections
range from superfcial skin lesions to oral thrush, vulvovaginal candidiasis, and bloodstream infections (BSIs).
In hospital intensive care units (ICUs), species of Candida are the third leading source of infection, responsible
for almost one-ffh of all ICU infections1. Within the general pediatric population, nearly 9% of all nosocomial
infections in Europe and the United States are due to Candida species2,3. More specifcally, Candida species are
the fourth-leading source of BSIs in the general population4. Within the pediatric population, candidemia is the
third-leading cause of BSIs2,3. Disseminated candidiasis has mortality rates reportedly ranging from 40–60% and 
results in nearly $2 billion in health care costs annually in the U.S. alone5,6. 
C. albicans, commensal of the gastrointestinal (GI) and reproductive tracts, oropharyngeal cavity, and skin
of humans is the predominant species of Candida linked to opportunistic infections and remains the leading
source of candidemia in ICUs worldwide4,7. However, the incidence of infections due to non-albicans species,
including C. glabrata, C. krusei, and C. parapsilosis, has increased globally particularly in Australia, the United
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States, and in Europe4. Treatment of Candida infections is challenging for clinicians as only three antifungal drug 
classes are available – azoles, polyenes, and echinocandins. Tough azoles, such as fuconazole, were the mainstay
treatment option for Candida infections for nearly two decades, a decrease in susceptibility to azoles by Candida
species has been reported5,8. Tus, recent guidelines in the U.S. and Europe have recommended the use of echi-
nocandins as frontline treatment options for Candida infections, and fuconazole for step-down therapy, particu-
larly for invasive infections in immunocompromised patients5,9,10. However, increased use of echinocandins has
resulted in more strains of C. albicans, C. glabrata, and C. parapsilosis exhibiting reduced susceptibility to echi-
nocandins4. Te emergence of the highly drug-resistant Candida auris, frst identifed in 2009 from a patient in
Japan, has compounded the treatment challenge associated with Candida infections. Te U.S. Centers for Disease
Control and Prevention (CDC) has reported that nearly 90% of C. auris isolates exhibit resistance to fuconazole, 
nearly 30% resistance to amphotericin B, and less than 5% resistance to echinocandins11. Te problem is worse in 
England where nearly all C. auris isolates exhibit resistance to fuconazole, almost 20% resistance to amphotericin
B, and nearly 10% resistance to echinocandins12. Of deep concern are C. auris isolates exhibiting resistance to
drugs in all three antifungal classes13,14. 
The limited number of antifungal drugs combined with the rise in resistance to current antifungals has
resulted in the U.S. CDC categorizing drug-resistant C. albicans and C. auris as urgent public health threats for
which new antifungal agents are needed15. Tis provided the impetus for us to evaluate a library of synthetic phe-
nylthiazole compounds, developed in-house, for antifungal activity against clinically-relevant species of Candida. 
Screening identifed one compound (1) as a promising lead compound with potent inhibitory activity against
fuconazole-resistant C. albicans. Te aim of this study was to investigate compound 1’s antifungal activity against
a wider panel of drug-resistant Candida isolates, ability to inhibit formation of and disrupt Candida bioflms, and
to protect nematodes infected with drug-resistant, highly-virulent strains of C. albicans and C. auris. 
Results 
Initial screening of phenylthiazole compound library against fluconazole-resistant C. albi-
cans. We initially evaluated the antifungal activity of 85 phenylthiazole compounds against C. albicans P60002,
which exhibited high-level resistance to fuconazole (MIC > 64 µg/mL) (Table S1). Of the compounds screened,
55 were inactive (MIC > 64 µg/mL) while 18 compounds exhibited weak antifungal activity (MIC ranged from
16 to 64 µg/mL). Eleven compounds exhibited moderate-to-good antifungal activity with MIC values against C. 
albicans P60002 of 2 µg/mL (for compound 10), 4 µg/mL (for compounds 2, 3, 11, 17, 21, 23 and 65), or 8 µg/mL
(for compounds 13, 19, and 36). Only compound 1 exhibited potent antifungal activity against C. albicans P60002
(MIC = 0.50 µg/mL), similar to the control antifungal amphotericin B. Tus compound 1 was selected as the lead 
compound for further investigation. 
Evaluation of compound 1’s antifungal activity against a wider panel of fungal isolates. Compound
1 was tested against a panel of fungal isolates to determine its spectrum of activity (Table 1). First, compound 1 was eval-
uated against fve additional C. albicans strains. Te compound showed potent antifungal activity (MIC=0.50µg/mL)
against two strains of fuconazole-sensitive C. albicans (MIC of fuconazole=0.50µg/mL) including one strain (NR-
29365) exhibiting resistance to amphotericin B (MIC=2µg/mL). Against two additional C. albicans strains (NR-29446
and ATCC MYA-573) exhibiting high-level resistance to fuconazole (MIC>64µg/mL), compound 1 was slightly
less efective (MIC=2µg/mL). Compound 1 also showed similar activity (MIC=2µg/mL) against C. albicans ATCC 
64124, a strain exhibiting resistance to both amphotericin B (MIC=2µg/mL) and fuconazole (MIC>64µg/mL). 
Te activity of compound 1 was evaluated next against non-albicans species of Candida, including strains
of C. auris, C. glabrata, C. parapsilosis, and C. tropicalis (Table 1). Compound 1 inhibited growth of all eight
strains of C. auris at a concentration of 2 µg/mL. Fluconazole was inefective against seven of the C. auris strains
(MIC > 64 µg/mL) while amphotericin B’s MIC values ranged from 0.50 to 2 µg/mL against the same strains.
Against two strains of C. glabrata resistant to fuconazole, compound 1 (MIC ranged from 0.25 to 1 µg/mL) was
as efective as amphotericin B (MIC ranged from 0.50 to 1 µg/mL). Against three strains of C. parapsilosis and C. 
tropicalis, compound 1 (MIC ranged from 0.50 to 1µg/mL) had similar potency to both fuconazole (MIC ranged
from 0.50 to 1 µg/mL) and amphotericin B (MIC = 0.50 µg/mL). MIC data for fuconazole determined against all 
strains of C. albicans (with the exception of C. albicans ATCC 64124), C. glabrata, C. parapsilosis, and C. tropicalis
were reported in a previous study16. 
Of the nearly 1.5 million deaths attributed to fungal infections globally each year, most fatalities are due to
species of Candida, Cryptococcus, and Aspergillus17. To gauge the spectrum of antifungal activity of the phenylth-
iazole compounds, we evaluated compound 1 against strains of pathogenic yeast (C. neoformans and C. gattii)
and molds (A. fumigatus) (Table 1). Against the three strains of Cryptococcus tested, compound 1 (MIC =0.50µg/
mL) was more potent than amphotericin B (MIC = 1 µg/mL) or fuconazole (MIC ranged from 2 to 8 µg/mL).
MIC data for fuconazole against all strains of Cryptococcus were reported in a previous study16. Against three
pathogenic strains of A. fumigatus, compound 1 (MIC ranged from 2 to 4 µg/mL) was as efective as amphotericin
B (MIC = 2 µg/mL) while fuconazole was inactive (MIC > 64 µg/mL). 
Compound 1 has fungicidal activity against both C. albicans and C. auris. To address whether
compound 1 exhibits fungistatic or fungicidal activity, a time-kill assay was conducted. Against C. albicans
P60002, compound 1 (at both 2 × MIC and 4 × MIC) exhibited rapid fungicidal activity, reducing fungal viability
below the limit of detection (10 CFU/mL) within 30 minutes (Fig. 1a). Tis was similar to the fungicidal efect
observed with amphotericin B18,19. No fungal regrowth was observed in the presence of either compound 1 or
amphotericin B during the assay (24 hours), indicating the absence of resistant mutants. A similar result was
obtained when compound 1 and amphotericin B were evaluated against C. auris strain 390. Compound 1 and
amphotericin B were both fungicidal with C. auris viability decreasing below the limit of detection (10 CFU/mL) 
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Fungal Strain Compound 1 Amphotericin B Fluconazole 
Candida albicans NR-29351 0.50 0.50 0.50a 
Candida albicans NR-29365 0.50 2 0.50a 
C. albicans NR-29446 2 0.50 >64a 
C. albicans 
ATCC MYA-573 2 1 >64
a 
C. albicans 
ATCC 64124 2 2 >64 
Candida auris 381 2 0.50 1 
Candida auris 383 2 1 >64 
Candida auris 384 2 1 >64 
Candida auris 385 2 2 >64 
Candida auris 386 2 2 >64 
Candida auris 387 2 1 >64 
Candida auris 389 2 2 >64 
Candida auris 390 2 2 >64 
Candida glabrata ATCC MYA-2950 1 1 32a 
Candida glabrata ATCC 66032 0.25 0.50 16a 
Candida parapsilosis ATCC 22019 0.50 0.50 1a 
Candida tropicalis ATCC 1369 1 0.50 1a 
Candida tropicalis ATCC 13803 1 0.50 0.50a 
Cryptococcus gattii NR-43208 0.50 1 2a 
Cryptococcus gattii NR-43209 0.50 1 8a 
Cryptococcus neoformans NR-41292 0.50 1 8a 
Aspergillus fumigatus NR-35302 2 2 >64 
Aspergillus fumigatus NR-35304 2 2 >64 
Aspergillus fumigatus NR-41312 4 2 >64 
Table 1. Antifungal activity (MIC, in µg/mL) of compound 1 against species of Candida, Cryptococcus, and 
Aspergillus. aMIC data previously presented in reference16. 
within 30 minutes and two hours, respectively (Fig. 1b). Itraconazole (at 4 ×MIC) exhibited bacteriostatic activity
against C. auris 390. Itraconazole (MIC =1µg/mL) was used in place of fuconazole as C. auris 390 is not sensitive
to fuconazole. We were unable to conduct a time-kill assay for azole antifungals against C. albicans P60002 as this
strain is highly-resistant to azoles, including to itraconazole (MIC > 16 µg/mL). 
Investigation of compound 1’s ability to inhibit Candida biofilm formation. A major vir-
ulence factor used by Candida species to evade the host immune response is the formation of bioflms. Te
three-dimensional structure of bioflms and the induction of drug efux pumps hinders penetration of most
antifungal drugs. Te formation of bioflms by Candida on the mucosa or endothelium in humans or on the sur-
face of implantable medical devices has been linked to recurrent infections and treatment failure with antifungal 
therapy20,21. Indeed Candida bioflms present on medical devices such as catheters and orthopedic implants ofen
are recalcitrant to treatment with antifungal drugs with the only recourse ofen is to remove and replace infected 
devices20. We therefore tested the ability of compound 1 to inhibit formation of bioflms by both C. albicans and C. 
auris using a standard microtiter dish bioflm formation assay. Compound 1 exhibited dose-dependent inhibition
of Candida bioflm formation. Against C. albicans P60002, at ¼ × MIC, compound 1 reduced bioflm formation
by 61.7% while amphotericin B reduced bioflm formation by 68.6% (Fig. 2a), relative to the untreated control
wells. At ½ × MIC, compound 1 (93.4% reduction) was more efective than amphotericin B (77% reduction) at
inhibiting C. albicans bioflm formation (P=0.0014). Amphotericin B (88.7% reduction) and compound 1 (94.2%
reduction) were equipotent at 1 ×MIC in inhibiting C. albicans bioflm formation. Both compound 1 and ampho-
tericin B were more efective at reducing bioflm formation by C. albicans than C. auris. When tested against C. 
auris strain 390, compound 1 was inefective at subinhibitory concentrations as it inhibited bioflm formation
only by 16.7% (at ¼ × MIC) and 20.1% (at ½ × MIC) (Fig. 2b). Amphotericin B was more efective at ¼ × MIC
and ½ × MIC, as it reduced C. auris bioflm formation by 39% (P = 0.0439; Fig. 2b) and 64.6% (P = 0.0263). At
1 × MIC, both compound 1 (91.2% reduction) and amphotericin B (92.4% reduction) were equally efective at
inhibiting C. auris bioflm formation (Fig. 2b). 
Compound 1 disrupts adherent Candida biofilms. Te ability of compound 1 to disrupt pre-formed
adherent bioflm was tested using the XTT reduction assay. Compound 1 showed concentration-dependent dis-
ruption of Candida bioflm metabolic activity. Against C. albicans P60002, compound 1 reduced the metabolic
activity of cells present in the bioflm by 5% (at 1 × MIC), 9.7% (at 2 × MIC; P = 0.0023), and 66.3% (at 4 × MIC; 
P < 0.0001), relative to the untreated control (Fig. 3a). Amphotericin B was more efective at higher concentra-
tions, where the drug (P < 0.0001) reduced metabolic activity of C. albicans present in the bioflm by 46.1% (at
1 × MIC), 56.8% (at 2 × MIC), and 76.6% (at 4 × MIC), relative to the untreated control. Both compound 1 and
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Figure 1. Time-kill analysis of compound 1, itraconazole, and amphotericin B. Test agents were evaluated 
against (a) C. albicans P60002 and (b) Candida auris strain 390 over a 24-hour incubation period at 35 °C. 
DMSO served as a negative control. Error bars represent standard deviation values. Dashed horizontal lines 
(---) represents the limit of detection (LOD) for the assay. 
amphotericin B, at higher concentrations, had potent antibioflm activity against C. auris strain 390. Compound 
1 significantly reduced the metabolic activity of cells present in the C. auris biofilm by 14.3% (at 1 × MIC;
P = 0.0112), 15.5% (at 2 × MIC; P = 0.0072), and 50.7% (at 4 × MIC; P < 0.0001), relative to the untreated con-
trol (Fig. 3b). Amphotericin B signifcantly reduced activity of C. auris cells in the bioflm by 12.7% (at 1 × MIC; 
P = 0.0212), 43.5% (at 2 × MIC; P < 0.0001), and 71.6% (at 4 × MIC; P < 0.0001), relative to untreated control. 
Safety profile of compound 1 against mammalian cells. Te toxicity of compound 1 to mammalian
cells was evaluated using a kidney epithelial cell line (Vero) at concentrations ranging from 8 to 64 µg/mL. No
acute toxicity was observed for Vero cells exposed to compound 1, up to the maximum concentration tested,
afer two hours of exposure. When the exposure was increased to 24 hours, Vero cells appeared unafected by
compound 1 up to 16 µg/mL (Fig. 4). Tis concentration is seven- to 31-fold higher than the MIC values for com-
pound 1 against all strains of Candida tested. 
Compound 1 is safe to nematodes and prolongs survival of nematodes infected with Candida.
Afer evaluating the safety profle of compound 1 to Vero cells, we evaluated the safety of compound 1 admin-
istered to C. elegans. Nematodes were exposed to 10, 20, 40, or 80 µg/mL of compound 1, and survival was
monitored daily (Fig. 5a). All worms exposed to either 10 or 40 µg/mL of compound 1 survived throughout the
duration of the study (four days). In the group exposed to 20µg/mL of compound 1, 97% of worms survived over 
four days (only one worm died). A concentration of 80 µg/mL compound 1 was found to be toxic as 50% of worms
died afer just three days and 75% died within four days.
Te efcacy of compound 1 was tested in a C. elegans model of Candida infection. As candidemia and dissem-
inated candidiasis tend to occur in immunocompromised adults and children, we utilized C. elegans AU37 (sek-1;
glp-4) strain (glp-4(bn2) nematodes, which are immunocompromised. Nematodes were infected with strains
of C. albicans (P60002) or C. auris (strain 390) exhibiting high-level resistance to fuconazole (MIC > 64 µg/ 
mL). Infected nematodes were subsequently treated with compound 1 (either 5 or 10 µg/mL), 5-Fluorocytosine
(5 µg/mL), or lef untreated and monitored daily for survival. Afer the second day post-infection, 94% of C. 
albicans-infected nematodes in the untreated group died and all nematodes were dead by the third day (Fig. 5b). 
In contrast, more than 70% of nematodes infected with C. albicans treated with compound 1 (both at 5 and 10 µg/
mL) survived three days afer infection. Afer four days, more than 70% of C. albicans-infected worms treated
with either compound 1 (at 5 µg/mL) or 5-Fluorocytosine were alive. 
Less than 20% of nematodes infected with C. auris survived three days post-infection in the untreated group, and
all were dead by the fourth day (Fig. 5c). Nearly half (48%) of nematodes treated with compound 1 (5µg/mL) survived
three days post-infection and 30% of worms survived up to four days. A higher dose of compound 1 (10µg/mL) pro-
longed survival of infected nematodes as nearly 70% were alive four days post-infection, similar to 5-Fluorocytosine. 
Discussion 
Candida infections are a signifcant healthcare problem globally. Te emergence of multidrug-resistant C. auris
isolates worldwide has exacerbated this treatment challenge. Te limited number of antifungal drugs com-
bined with the development of resistance to these agents presents a challenge to treat invasive Candida infec-
tions. Existing antifungal drugs have a number of drawbacks including narrow antifungal spectrum, undesirable 
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Figure 2. Inhibition of Candida bioflm formation. Compound 1 and amphotericin B were evaluated for 
their ability to inhibit bioflm formation by (a) C. albicans P60002 and (b) C. auris strain 390. An overnight 
suspension of C. albicans was diluted in RPMI-1640 medium supplemented with MOPS (to achieve a starting 
inoculum ~5 × 105 CFU/mL) and exposed to compound 1 or amphotericin B (at the indicated concentrations) 
or lef untreated for 24 hours at 35 °C to permit bioflm formation. Te bioflm was stained with 0.1% crystal 
violet, de-stained with ethanol, and bioflm mass quantifed at OD595. Data represents percent inhibition of 
bioflm mass by compound 1 relative to the untreated control. Data were analyzed via an unpaired one-way 
t-test (P < 0.05). Asterisks (*) indicate statistical diference between amphotericin B-treated and compound 
1-treated wells. 
drug-drug interactions due to the inhibition or induction of cytochrome P450 enzymes (particularly for azoles), 
toxicity to host tissues (such as nephrotoxicity for polyenes and hepatotoxicity for 5-Fluorocytosine), and a lack
of suitable oral formulations (namely for polyenes and echinocandins)5,10,22. Tough several new antifungal agents
are currently being investigated in clinical trials, the small number of antifungals with unique mechanisms of
action combined with the low success rate of anti-infectives to receive regulatory approval necessitates the ongo-
ing need to discover new antifungal agents5,10,23. 
Tiazole compounds are ofen present in natural products and have been found to have potent anti-infective
properties including as antibacterial, antimalarial, and antiviral agents24. Additionally, as discussed by Singh et
al., more than 20 FDA-approved drugs and over 70 experimental drugs contain the thiazole scafold in their
core structure, highlighting the importance of this scafold in drug discovery24. Moreover, several phenylthiazole 
compounds have been reported to possess antifungal activity against C. albicans and species of Cryptococcus25–27. 
In the present study we evaluated 85 phenylthiazole small molecules, developed in-house, for antifungal activity 
against fuconazole-resistant C. albicans P60002. Previously these small molecules were extensively investigated as
antibacterial agents against drug-resistant staphylococci and enterococci28–35. Interestingly, the most potent phe-
nylthiazole compounds with antibacterial activity were generally less efective against C. albicans. For example,
compounds 2 and 3 inhibited growth of drug-resistant S. aureus isolates at a concentration as low as 0.50 µg/mL
and 0.70 µg/mL, respectively31,32. However, both compounds inhibited growth of C. albicans P60002 at 4 µg/mL.
More than 70 of the phenylthiazole compounds tested exhibited weak antifungal activity (MIC ranged between
16 to 64µg/mL) or were inactive against C. albicans P60002. Compound 1 was selected for further investigation as
it was the molecule with the strongest antifungal activity (MIC = 0.50 µg/mL), with a potency similar to ampho-
tericin B. 
A limitation with certain frst-generation triazole antifungals, such as fuconazole, is their narrow spectrum
of activity. Recently, increased resistance to azoles has been observed both in non-albicans Candida species as
well as in isolates of A. fumigatus10. Tus, we evaluated whether compound 1 would exhibit a limited spectrum
of antifungal activity similar to fuconazole. Compound 1’s antifungal activity was assessed against a broad range 
of Candida species (including strains of C. auris, C. glabrata, C. parapsilosis, and C. tropicalis) as well as against
other important pathogenic fungi (namely species of Cryptococcus and Aspergillus). Against eight C. auris isolates
tested, compound 1 inhibited growth of these strains at 2µg/mL which was superior to fuconazole (MIC> 64 µg/
mL for seven isolates) and nearly equipotent to amphotericin B (MIC ranged from 0.50 to 2 µg/mL). Against C. 
glabrata isolates resistant to fuconazole (MIC ranged from 16 to 32 µg/mL), compound 1 (MIC ranged from
0.25 to 1 µg/mL) exhibited similar potency to amphotericin B (MIC ranged from 0.50 to 1 µg/mL). Compound 1
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Figure 3. Antibioflm activity of compound 1 and amphotericin B against mature Candida bioflm. Test agents 
were evaluated against (a) C. albicans P60002 and (b) C. auris strain 390 adherent bioflm evaluated with the 
XTT assay. Adherent bioflms were treated with either compound 1 or amphotericin B (both in triplicate) at 
the concentrations presented, over a 24-hour period. Te percent metabolic activity for each treatment was 
calculated relative to untreated wells. Error bars represent standard deviation values. Asterisk denotes statistical 
diference between compound 1 and amphotericin B relative to the negative control (untreated wells) evaluated 
using a two-way ANOVA, with post hoc Dunnet’s test for multiple comparisons (P < 0.05). 
Figure 4. Toxicity of compound 1 against monkey kidney epithelial cells (Vero). Cells were exposed to 
compound 1 for 24 hours. Data represent percent viable cells afer exposure to the compound (tested in 
triplicate) at 8, 16, 32, and 64 μg/mL using the MTS assay. Dimethyl sulfoxide (DMSO) was used as a negative 
control. Error bars represent standard deviation values. An asterisk (*) denotes statistical diference between 
compound 1 and DMSO evaluated using a two-way ANOVA, with post hoc Sidak’s multiple comparisons test 
(P < 0.05). 
possessed similar activity as both fuconazole and amphotericin B against isolates of C. parapsilosis and C. tropi-
calis (MIC ranged between 0.50 and 1 µg/mL). Compound 1 was more potent than both amphotericin B and fu-
conazole against strains of Cryptococcus neoformans and C. gattii while compound 1 displayed similar antifungal 
activity to amphotericin B against strains of Aspergillus fumigatus. Overall, compound 1 displayed a broader spec-
trum of antifungal activity, compared to fuconazole, against species of Candida, Cryptococcus, and Aspergillus. 
As invasive Candida infections tend to occur in immunocompromised patients, a fungicidal agent would be
advantageous in reducing the burden of or completely eliminating the pathogen in infected patients36. Utilizing
a standard time-kill assay, compound 1 (at both 2 × MIC and 4 × MIC) demonstrated rapid fungicidal activity,
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Figure 5. Toxicity of compound 1 and efcacy of compound 1 and 5-Fluorocytosine in C. elegans infected with 
C. albicans or C. auris. (a) Adult (L4-stage) worms were exposed to compound 1 at four diferent concentrations 
and viability was recorded daily for four days. Adult (L4-stage) worms were infected with the highly-virulent, 
fuconazole-resistant strains (b) C. albicans P60002 or (c) C. auris strain 390 for 90 minutes at 25 °C. Worms 
were washed and then treated with compound 1 (either at 5 µg/mL or 10 µg/mL), 5-Fluorocytosine (5-FC, 5 µg/ 
mL) or lef untreated. Survival of worms was monitored daily and recorded. Data are presented as a Kaplan-
Meier survival curve. 
reducing the inoculum of both C. albicans P60002 and C. auris strain 390 below the limit of detection within
30 minutes. Amphotericin B required two hours to achieve the same efect against both strains of Candida. 
Interestingly, compound 1 was previously found to exhibit rapid bactericidal activity in vitro against bacteria.
Against methicillin-resistant Staphylococcus aureus USA300, vancomycin-resistant Enterococcus faecium ATCC
700221, and vancomycin-resistant Enterococcus faecalis HM-201, compound 1 completely eliminated the bacte-
rial inoculum within two hours31,33. A concern with rapidly -cidal agents is they may exert their efect through
disruption of the cell membrane, which may be non-specifc and lead to toxicity to host tissues. However, com-
pound 1 was previously shown not to physically disrupt bacterial cell membranes through standard cell leak-
age assays and through bacterial cytological profling31,33. We also did not observe an increase in the leakage of
intracellular contents when Candida cells were exposed to a high concentration of compound 1 (Supplementary 
Fig. S1), indicating the compound does not physically disrupt the integrity of the fungal cell membrane.
It has been reported by the National Institutes of Health that bioflms contribute to more than 80% of all
microbial infections in the United States7. As noted earlier, bioflms tend to form on the surfaces of medical
devices and host tissues. Both C. albicans and C. auris are capable of forming bioflms although C. albicans is a 
more prominent bioflm producer amongst all Candida species20. C. auris tends to form thinner bioflms due to
the lack of pseudohyphae which may hinder its ability to attach to certain surfaces, a necessary initial step to form
robust bioflms13. Current approaches to inhibit Candida bioflm formation in medical devices such as catheters
include coating the surface with antifungal agents or the use of “lock therapy” whereby a high concentration of an
antifungal agent slowly difuses through the lumen of a catheter before insertion of the catheter into a patient20. As
compound 1 was very efective in inhibiting growth of planktonic Candida cells, we investigated the compound’s 
ability to inhibit Candida bioflm formation via the crystal violet reporter assay. Compound 1 was more efec-
tive at inhibiting C. albicans bioflm formation compared to inhibiting C. auris bioflm formation. At ½ × MIC,
compound 1 was more efective than amphotericin B at reducing C. albicans bioflm formation by more than
93%. In contrast, compound 1 (at ½ × MIC) reduced C. auris bioflm formation by only 20.1%. Amphotericin
8 SCIENTIFIC REPORTS |         (2019) 9:18941  | https://doi.org/10.1038/s41598-019-55379-1 
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B (at ½ × MIC) was more efective as it reduced C. auris bioflm formation by 64.6%. Both amphotericin B and
compound 1 successfully inhibited C. auris bioflm formation at 1 × MIC similar to the result observed against
C. albicans. 
Once bioflms form, they are very difcult to eradicate in part due to enhanced resistance to antimicrobial
agents which can lead to persistent recurring infections in patients. Of the three antifungal drug classes used clin-
ically to treat Candida infections, azoles tend to be the least efective at disrupting Candida bioflms while echino-
candins and lipid formulations of amphotericin B are more efective37. Multiple factors contribute to the reduced 
sensitivity of Candida bioflms to antifungal therapy. However, the presence of persister cells and secretion of
extracellular polymeric substances (EPS) are key factors20. EPS plays a prominent role in decreasing difusion of
antifungal agents through the bioflm matrix and limits phagocytosis of Candida cells by host immune cells20. 
Finding antifungal agents capable of disrupting adherent Candida bioflms would thus be benefcial. Compound 
1 previously was shown to be capable of signifcantly disrupting adherent bioflms formed by Staphylococcus
epidermidis in vitro38. Tis motivated us to evaluate if the compound would be efective in disrupting Candida
bioflms. Utilizing the XTT reduction assay, compound 1, at 4 × MIC, successfully reduced the metabolic activity
of cells present in both C. albicans and C. auris adherent bioflms by 66% and 50%, respectively. Amphotericin
B, at the same test concentration, reduced the metabolic activity of cells present in both C. albicans and C. auris
adherent bioflms by 76% and 71%, respectively. Tus, in addition to compound 1 possessing potent in vitro anti-
fungal activity against planktonic cells, the compound also possesses antibioflm activity against both C. albicans
and C. auris. 
Te promising antifungal and antibioflm activity of compound 1 in vitro encouraged us to evaluate this com-
pound in a preliminary in vivo nematode model of Candida infection. However, prior to testing compound 1 in 
nematodes, we evaluated the compound’s safety profle to mammalian cells. Compound 1 was incubated with
Vero (kidney epithelial) cells for either two or 24 hours before detecting viability of cells using the MTS assay. At 
the maximum concentration tested (64 µg/mL), compound 1 was safe to Vero cells afer two hours of exposure.
When the exposure time was increased to 24 hours, more than 90% of Vero cells remained viable when exposed
to compound 1 (at 16 µg/mL). At 32 and 64 µg/mL, more than 60% of Vero cells remained viable afer 24 hours of 
exposure to compound 1. Previous reports have indicated that the IC50 of amphotericin B, a nephrotoxic drug, to 
Vero cells is 24.4 µg/mL, which suggests that compound 1 may be potentially safer to mammalian cells compared 
to amphotericin B25. 
Afer confrming compound 1’s safety profle to Vero cells, we moved to evaluate compound 1’s antifungal
efcacy in a C. elegans model of Candida infection. C. elegans is a well-established early-stage animal model for
evaluating small molecules with anti-infective activity and has been used as an in vivo model for Candida infec-
tions previously39. An immunocompromised strain of C. elegans was infected with the highly-virulent strains
of C. albicans P60002 or C. auris strain 390 and subsequently treated with compound 1 (at 5 or 10 µg/mL) or
5-Fluorocytosine (at 5 µg/mL). Te concentrations used for compound 1 were safe to C. elegans, as previously
this compound was reported to be non-toxic to C. elegans up to a concentration of 20 µg/mL33. In this study, we
monitored survival of nematodes exposed to compound 1 at concentrations ranging from 10 to 80 µg/mL. All
worms exposed to compound 1 at 10 or 40 µg/mL survived for four days while 75% of worms exposed to 80 µg/
mL compound 1 died within four days. When nematodes were infected with Candida, compound 1 successfully 
prolonged survival of nematodes infected with either C. albicans or C. auris. Nearly 95% of untreated nematodes 
infected with C. albicans were dead by the second day post-infection and all remaining nematodes had died by the
third day. In contrast, afer four days post-infection, more than 70% of C. albicans-infected worms treated with
either compound 1 (at 5 µg/mL) or the control antifungal drug 5-Fluorocytosine were alive. 5-Fluorocytosine is
used clinically, ofen in combination with amphotericin B, for treatment of endocarditis, meningitis, and pyelo-
nephritis caused by Candida species that are not susceptible to fuconazole treatment9. More than 80% of nema-
todes infected with C. auris died within three days post-infection and all were dead by the fourth day. In contrast,
30% of C. auris-infected nematodes remained alive when treated with 5 µg/mL of compound 1, afer four days
post-infection. We suspect that the enhanced efcacy of compound 1, at 5µg/mL, to prolong survival of C. elegans
infected with C. albicans compared to C. auris may be attributed to a diference in potency against C. albicans
P60002 (MIC = 0.5 µg/mL) compared to C. auris strain 390 (MIC = 2 µg/mL). Indeed, when treated with a higher
concentration of compound 1 (10 µg/mL), nearly 70% of worms infected with C. auris survived up to four days
post-infection. Amphotericin B was not used as a positive control in the C. elegans study because C. auris strain
390 is resistant to this drug. Furthermore, in a pilot study, amphotericin B (both at 5 and 10 µg/mL) was found to 
be inefective in prolonging survival of C. elegans infected with C. albicans P60002. 
We attempted to determine the antifungal mechanism of action of compound 1. Synthetic compounds con-
taining the thiazole ring have been shown to inhibit diferent molecular targets/processes in fungi including
leucyl-tRNA synthetase, the fungal antioxidant system through increased generation of reactive oxygen species,
and interference with the fungal cell wall27,40,41. Previous reports have also identifed an array of genes involved
in Candida bioflm formation, including genes corresponding to proteins involved in mannan and β-1,6-glucan
synthesis, two important polysaccharides that form the EPS matrix in bioflms20,37. In order to identify its mech-
anism(s) of action, compound 1 was subjected to chemogenomic profling against more than 6,000 heterozygous 
diploid deletion strains of the model yeast Saccharomyces cerevisiae. We previously used this method to deter-
mine the antifungal mechanism of action of a synthetic compound, a molecule currently in clinical trials, and
an FDA-approved drug which displayed potent activity against diferent Candida species16,42,43.We were unable
to determine the antifungal or antibioflm mechanism of compound 1 via chemogenomic profling. In bacteria,
compound 1 interferes with cell wall biosynthesis through dual inhibition of the undecaprenyl diphosphate phos-
phatase and undecaprenyl diphosphate synthase enzymes33. We investigated if similar enzymes might be a target 
of compound 1 by testing Candida strains that were heterozygous for homologous genes encoding these enzymes.
Strains heterozygous for a gene encoding a compound target should exhibit increased growth sensitivity than the 







    
 
















   
    
     
       
   
  
   
   
   
  
 
   
  
    
  








           
isogenic wild-type strain42,43. We tested heterozygous strains encoding homologous genes in the dolicol phosphate
metabolism pathway including dolichyl pyrophosphate phosphatase (CWH8/C1_02250W_A) and two enzymes 
with dehydrodolichyl diphosphate synthase activity (RER2/C5_05330C_A and SRT1/C1_12270W_A)44–46. None
of these strains exhibited increased sensitivity compared to wild-type in a minimum inhibitory concentration
assay (Supplementary Table S2) and in the viability of the strains afer 24 hours incubation with the compound,
both in standard (RPMI-1640) and nutrient-rich (YPD) media. CWH8 and RER2 may be essential in C. albicans
based on a stable haploid-based large-scale survey whereas these genes are not essential in S. cerevisiae47. Te 
lack of strain sensitivity suggests that these enzymes may not be the direct or sole target of compound 1. Further 
investigation is needed to clarify the mechanism(s) of action of compound 1. 
Methods 
Synthesis of phenylthiazole compounds. Compounds were synthesized and characterized as described
in previous reports. Te synthetic schemes for compounds 1-2329,31,35,48,49, compounds 24-3128, and compounds
32-8530,34,50,51 are presented in the supplementary information fle. Compounds were prepared as stock 10 mg/mL
or 1 mg/mL solutions in dimethyl sulfoxide (DMSO). 
Fungal strains and reagents used in this study. Clinical isolates of all fungal species (Supplementary
Table S3) were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA), BEI Resources
(Manassas, VA, USA), or the U.S. CDC (Atlanta, GA, USA). Vero cells (strain NR-10385) were acquired from
BEI Resources. Amphotericin B (Fisher Scientifc, Fair Lawn, NJ, USA), itraconazole (TCI, Ltd., Tokyo, Japan),
5-Fluorocytosine (TCI, Ltd., Tokyo, Japan), and fuconazole (Acros Organics, New Jersey, USA) were acquired
from commercial vendors. Both amphotericin B and fuconazole were dissolved in DMSO to prepare stock 10 mg/
mL solutions. Yeast extract peptone dextrose (YPD, Becton, Dickinson, and Company, Sparks, MD, USA), RPMI-
1640 (Gibco, Grand, Island, NY, USA), 3-(N-morpholino)propanesulfonic acid (MOPS, Fisher Scientifc, Fair
Lawn, NJ, USA), phosphate-bufered saline (PBS, Corning, Manassas, VA, USA), minimum essential medium
(MEM, Gibco, Grand Island, NY, USA), sodium pyruvate (Sigma-Aldrich, St. Louis, MO, USA), fetal bovine
serum (FBS, Corning, Manassas, VA, USA), penicillin-streptomycin (Gibco, Grand Island, NY, USA), crystal
violet (Acros Organics, New Jersey, USA), sodium 3′-[1-[(phenylamino)-carbony]-3,4-tetrazolium]-bis(4-m
ethoxy-6-nitro)benzene-sulfonic acid hydrate (XTT, Sigma-Aldrich, St. Louis, MO, USA), and 96-well plates
(CellTreat, Pepperell, MA, USA) were all purchased from commercial vendors. 
Determination of minimum inhibitory concentration (MIC). Te MIC of compounds and control
drugs was determined as per the guidelines by the Clinical and Laboratory Standards Institute for yeasts (M27,
4th Edition) and molds (M38-A2)52,53. Microtiter plates containing fungi and compounds/drugs were incubated
at 35–37 °C for at least 24 hours for Candida spp. and Aspergillus spp. or 72 hours for Cryptococcus spp. Te MIC 
was confrmed via visual inspection of growth at each test concentration. 
Time-kill assay against Candida species. Fungal suspensions of C. albicans P60002 and C. auris 390 cells
were separately diluted to 3.63 × 104 and 7.2 × 104 colony-forming units per milliliter (CFU/mL), respectively.
Te suspensions were exposed to either compound 1 (at either 2 × MIC or 4 × MIC), itraconazole (4 × MIC),
or amphotericin B (4 × MIC) (in duplicate) in RPMI-1640 medium supplemented with MOPS. At specifc time
points, a sample was collected, diluted in PBS, and an aliquot of each dilution was transferred to YPD agar plates. 
Plates were incubated at 35 °C for 24 hours before viable CFU/mL was determined. 
Investigation of compound 1’s ability to inhibit C. albicans or C. auris biofilm formation.
Overnight suspensions of C. albicans P60002 or C. auris 390 were centrifuged (4000× g for fve minutes), washed
with PBS, and adjusted to a starting inoculum of ~5.0 × 105 CFU/mL in RPMI-1640 supplemented with MOPS,
as described in a previous report16. Aliquots (150µL) of fungal suspensions of C. albicans P60002 and C. auris 390
were separately transferred to each well of a 96-well tissue-culture treated plate. Compound 1 or amphotericin B 
(at least two replicates per test agent) were added and serially diluted to create a concentration gradient. Te plate
was incubated for 24 hours at 35 °C to permit bioflm formation, as described previously16. Te inoculum was
removed and bioflms were washed three times with PBS (to remove planktonic fungi). Bioflm mass was quan-
tifed (OD595) using the crystal violet reporter assay54. Te bioflm inhibition data were analyzed via an unpaired 
one-way t-test (P < 0.05), utilizing GraphPad Prism 6.0 (GraphPad Sofware, La Jolla, CA). 
Inhibition of metabolism in adherent C. albicans or C. auris biofilm. Overnight suspensions of C. 
albicans P60002 or C. auris 390 were prepared as described above. Aliquots (150µL) of the fungal suspensions were
placed in each well of a 96-well tissue-culture treated plate and incubated for 24 hours at 35 °C to form adherent
bioflm, as per a previous report16. Te inoculum was removed and bioflms were washed three times with PBS
(to remove planktonic fungi). Test agents (at least two replicates per agent) were added (in RPMI-1640 medium
supplemented with MOPS), serially diluted, and incubated with the Candida bioflms for 24hours at 35°C. Te via-
bility of cells in the bioflm was determined using the XTT reduction assay55. Data were analyzed using a two-way
ANOVA, with post hoc Dunnet’s multiple comparisons test (P<0.05) (GraphPad Sofware, La Jolla, CA). 
Safety profile of compound 1 against Vero cells. Compound 1 was evaluated against monkey kidney
epithelial cells (Vero) to determine the potential toxic efect to mammalian cells in vitro, as described elsewhere16. 
Cells were cultured in MEM supplemented with 10% FBS, 1mM sodium pyruvate, and penicillin-streptomycin at
37 °C with CO2 (5%). Control cells received DMSO alone at a concentration equal to that in drug-treated samples.
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Te cells were incubated with compound 1 (in triplicate) in a 96-well plate at 37 °C with CO2 (5%) for either two 
or 24 hours. Te assay reagent MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophe
nyl)-2H-tetrazolium) (Promega, Madison, WI, USA) was subsequently added and the plate was incubated for
four hours. Absorbance readings (at OD490) were taken using a kinetic microplate reader (Molecular Devices,
Sunnyvale, CA, USA). Te quantity of viable cells afer treatment with each compound was expressed as a per-
centage of the viability of DMSO-treated control cells (average of triplicate wells ± standard deviation). Te toxic-
ity data were analyzed via a two-way ANOVA, with post hoc Sidak’s multiple comparisons test (P<0.05), utilizing
GraphPad Prism 6.0 (GraphPad Sofware, La Jolla, CA). 
Infection of Caenorhabditis elegans with C. albicans or C. auris and treatment with compound 1.
L4-stage C. elegans AU37 (sek-1; glp-4) strain (glp-4(bn2) were used to assess the toxicity and efcacy of com-
pound 1 to enhance survival of worms infected with either C. albicans or C. auris, using a previously described
method16,43. For toxicity assessment, nematodes were exposed to either 10, 20, 40, or 80 µg/mL of compound 1
and survival of nematodes was checked and recorded daily for four days. For efcacy studies, fuconazole-resistant
C. albicans P60002 or C. auris strain 390 was grown to log-phase (~1 × 107 CFU/mL) in YPD broth. Nematodes
(20–39) were added to the broth and infected with fungi for 90 minutes at 25 °C. Worms were then harvested by
centrifugation, washed at least fve times with sterile PBS, and subsequently treated with compound 1 (either 5 or
10 µg/mL) or 5-Fluorocytosine (5 µg/mL). One group of worms was lef untreated as a negative control. Viability 
of nematodes was checked and recorded daily. Data are presented as percent survival of infected C. elegans uti-
lizing a Kaplan-Meier survival curve generated using GraphPad Prism 6.0 (GraphPad Sofware, La Jolla, CA). 
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